Search

Your search keyword '"Parmiani, G"' showing total 916 results
Start Over Author "Parmiani, G"
916 results on '"Parmiani, G"'

4. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Author

Di Giacomo, A. M., Ascierto, P. A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., Orgiano, L., Spadola, G., Del Vecchio, M., Danielli, R., Calabrò, L., Annesi, D., Giannarelli, D., Maccalli, C., Fonsatti, E., Parmiani, G., and Maio, M.

Published
2015
Full Text
View/download PDF

16. Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008

Author

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G, Aimone P, Cignetti A, Casorati G, Castelli C, Del Vecchio M, Di Giacomo AM, Di Nicola M, Fais F, Ferrini S, Fontana R, Iovino F, Lander T, Maccalli C, Manfredi A, Neyroz P, Nisticò P, Pellegatta S, Proietti E, Rivoltini L, Rosato A, Santoni A, Sigalotti L., LOLLINI, PIER LUIGI, Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G, Aimone P, Cignetti A, Casorati G, Castelli C, Del Vecchio M, Di Giacomo AM, Di Nicola M, Fais F, Ferrini S, Fontana R, Iovino F, Lander T, Lollini PL, Maccalli C, Manfredi A, Neyroz P, Nisticò P, Pellegatta S, Proietti E, Rivoltini L, Rosato A, Santoni A, and Sigalotti L

Subjects
Cancer Research, Oncology, Immunology, Immunology and Allergy
Published
2009
Full Text
View/download PDF

17. Preliminary results of contrast-enhanced sonography in the evaluation of the response of uveal melanoma to gamma-knife radiosurgery

Author

Venturini, M, Colantoni, C, Modorati, G, Di Nicola, M, Colucci, A, Agostini, G, Picozzi, P, Parmiani, G, DE COBELLI, FRANCESCO, MORTINI, PIETRO, BANDELLO, FRANCESCO, DEL MASCHIO, ALESSANDRO, Venturini, M, Colantoni, C, Modorati, G, Di Nicola, M, Colucci, A, Agostini, G, Picozzi, P, DE COBELLI, Francesco, Parmiani, G, Mortini, Pietro, Bandello, Francesco, and DEL MASCHIO, Alessandro

Subjects
Uveal melanoma, Contrast-enhanced ultrasonography, Gamma-knife radiosurger
Abstract

Purpose: Our aim was to prospectively analyze the use of contrast-enhanced ultrasound (CEUS) in the quantitative assessment of the response of uveal melanoma (UM) to gamma-knife radiosurgery (GKR), investigating whether changes in tumor vascularization precede thickness reduction, which on average occurs at 12 months after GKR. Methods: Ten patients with UM treated with GKR underwent sonography (US) and CEUS at baseline and at 3, 6, and 12 months after GKR. The transverse diameter, thickness, and quantitative parameters of the UM (ie, area under the curve in the wash-in phase, wash-in perfusion index, peak enhancement, and wash-in rate) were calculated by using dedicated software and compared by using Wilcoxon's signed-rank test. Results: The mean tumor thickness on US was significantly less at both 6 (6.6 mm) and 12 months after GKR (5.8 mm) than it was at baseline (8.3 mm; p

Published
2015

18. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes

Author

Mennonna, D, Maccalli, C, Romano, M, Garavaglia, C, Capocefalo, F, Bordoni, R, Severgnini, M, De Bellis, G, Sidney, J, Sette, A, Gori, A, Longhi, R, Braga, M, Ghirardelli, L, Baldari, L, Orsenigo, E, Albarello, L, Zino, E, Fleischhauer, K, Mazzola, G, Ferrero, N, Amoroso, A, Casorati, G, Parmiani, G, Dellabona, P, Mennonna, Daniele, Maccalli, Cristina, Romano, Michele C., Garavaglia, Claudio, Capocefalo, Filippo, Bordoni, Roberta, Severgnini, Marco, De Bellis, Gianluca, Sidney, John, Sette, Alessandro, Gori, Alessandro, Longhi, Renato, Braga, Marco, Ghirardelli, Luca, Baldari, Ludovica, Orsenigo, Elena, Albarello, Luca, Zino, Elisabetta, Fleischhauer, Katharina, Mazzola, Gina, Ferrero, Norma, Amoroso, Antonio, Casorati, Giulia, Parmiani, Giorgio, Dellabona, Paolo, Mennonna, D, Maccalli, C, Romano, M, Garavaglia, C, Capocefalo, F, Bordoni, R, Severgnini, M, De Bellis, G, Sidney, J, Sette, A, Gori, A, Longhi, R, Braga, M, Ghirardelli, L, Baldari, L, Orsenigo, E, Albarello, L, Zino, E, Fleischhauer, K, Mazzola, G, Ferrero, N, Amoroso, A, Casorati, G, Parmiani, G, Dellabona, P, Mennonna, Daniele, Maccalli, Cristina, Romano, Michele C., Garavaglia, Claudio, Capocefalo, Filippo, Bordoni, Roberta, Severgnini, Marco, De Bellis, Gianluca, Sidney, John, Sette, Alessandro, Gori, Alessandro, Longhi, Renato, Braga, Marco, Ghirardelli, Luca, Baldari, Ludovica, Orsenigo, Elena, Albarello, Luca, Zino, Elisabetta, Fleischhauer, Katharina, Mazzola, Gina, Ferrero, Norma, Amoroso, Antonio, Casorati, Giulia, Parmiani, Giorgio, and Dellabona, Paolo

Abstract

Objective Patient-specific (unique) tumour antigens, encoded by somatically mutated cancer genes, generate neoepitopes that are implicated in the induction of tumour-controlling T cell responses. Recent advancements in massive DNA sequencing combined with robust T cell epitope predictions have allowed their systematic identification in several malignancies. Design We undertook the identification of unique neoepitopes in colorectal cancers (CRCs) by using high-throughput sequencing of cDNAs expressed by standard cancer cell cultures, and by related cancer stem/initiating cells (CSCs) cultures, coupled with a reverse immunology approach not requiring human leukocyte antigen (HLA) allele-specific epitope predictions. Results Several unique mutated antigens of CRC, shared by standard cancer and related CSC cultures, were identified by this strategy. CD8+ and CD4+ T cells, either autologous to the patient or derived from HLA-matched healthy donors, were readily expanded in vitro by peptides spanning different cancer mutations and specifically recognised differentiated cancer cells and CSC cultures, expressing the mutations. Neoepitope-specific CD8+ T cell frequency was also increased in a patient, compared with healthy donors, supporting the occurrence of clonal expansion in vivo. Conclusions These results provide a proof-of-concept approach for the identification of unique neoepitopes that are immunogenic in patients with CRC and can also target T cells against the most aggressive CSC component.

Published
2017

21. Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell-Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4

Author

Volontè, A, Di Tomaso, T, Spinelli, M, Sanvito, F, Alabarello, L, Bissolati, M, Ghirardelii, L. Orsenigo, E, Ferrone, S, Doglioni, C, STASSI, Giorgio, Dellabona, P, Staudacher, C, Parmiani, G, Maccalli, C, TODARO, Matilde, Volonte, Andrea, Di Tomaso, Tiziano, Spinelli, Michela, Todaro, Matilde, Sanvito, Francesca, Albarello, Luca, Bissolati, Massimiliano, Ghirardelli, Luca, Orsenigo, Elena, Ferrone, Soldano, Doglioni, Claudio, Stassi, Giorgio, Dellabona, Paolo, Staudacher, Carlo, Parmiani, Giorgio, Maccalli, Cristina, Volontè, A, Di Tomaso, T, Spinelli, M, Sanvito, F, Alabarello, L, Bissolati, M, Ghirardelii, L Orsenigo, E, Ferrone, S, Doglioni, C, Stassi, G, Dellabona, P, Staudacher, C, Parmiani, G, Maccalli, C, and Todaro, M

Subjects
medicine.medical_treatment, T cell, T-Lymphocytes, Immunology, Tumor initiation, Cell Communication, Lymphocyte Activation, Article, Immune system, Antigen, Antigens, Neoplasm, Cell Line, Tumor, Spheroids, Cellular, medicine, Tumor Cells, Cultured, Immunology and Allergy, Humans, Immunologic Surveillance, Interleukin 4, Settore MED/04 - Patologia Generale, biology, CD44, Cell Membrane, Immunotherapy, Immunosurveillance, medicine.anatomical_structure, biology.protein, Neoplastic Stem Cells, Tumor Escape, Interleukin-4, Colorectal Neoplasms, IL-4, Cancer-initiating cells (CICs)
Abstract

Cancer-initiating cells (CICs) that are responsible for tumor initiation, propagation, and resistance to standard therapies have been isolated from human solid tumors, including colorectal cancer (CRC). The aim of this study was to obtain an immunological profile of CRC-derived CICs and to identify CIC-associated target molecules for T cell immunotherapy. We have isolated cells with CIC properties along with their putative non-CIC autologous counterparts from human primary CRC tissues. These CICs have been shown to display “tumor-initiating/stemness” properties, including the expression of CIC-associated markers (e.g., CD44, CD24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenicity following injection in immunodeficient mice. The immune profile of these cells was assessed by phenotype analysis and by in vitro stimulation of PBMCs with CICs as a source of Ags. CICs, compared with non-CIC counterparts, showed weak immunogenicity. This feature correlated with the expression of high levels of immunomodulatory molecules, such as IL-4, and with CIC-mediated inhibitory activity for anti-tumor T cell responses. CIC-associated IL-4 was found to be responsible for this negative function, which requires cell-to-cell contact with T lymphocytes and which is impaired by blocking IL-4 signaling. In addition, the CRC-associated Ag COA-1 was found to be expressed by CICs and to represent, in an autologous setting, a target molecule for anti-tumor T cells. Our study provides relevant information that may contribute to designing new immunotherapy protocols to target CICs in CRC patients.

Published
2014

22. 'Cancer Bio-Immunotherapy in Siena': Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015

Author

Maio, M., Bertocci, E., Fazio, C., Chiarucci, C., Cutaia, O., Scala, E., Giacobini, G., Lofiego, M. F., Fonsatti, E., Maccalli, C., Nicolay, H. J. M. G., Parmiani, G., Bronte, V., Seliger, B., Rivoltini, L., Sica, A., Squadrito, M. L., Rammensee, H. -G., Sahin, U., Schuler, G., Trajanoski, Z., Fridman, W. H., Marincola, F. M., Anichini, A., Calcinotto, A., Huber, S., Pozzi, C., Corna, G., Coulie, P., Figini, M., Calabrò, L., Ferrone, S., Buccione, C., Tagliamonte, M., Huber, C., Giordano, M., Astra Zeneca, R. I., Cuillerot, J. -M., Chartash, E., Azab, M., Colombo, M. P., Carbone, E., Martinoli, C., Nistico’, P., Garlanda, C., Di Giacomo, A. M., Straten, P. T., Oliveira, G., Moretta, L., Zuccolotto, G., Monfardini, S., and Nibit

Subjects
Cancer Research, Checkpoint blockade agents, business.industry, medicine.medical_treatment, Immunology, Cancer, Library science, Cancer vaccines, Immunotherapy, NIBIT, Targeted therapies, medicine.disease, Oncology, medicine, Immunology and Allergy, business
Published
2016

26. Basi scientifiche per la definizione di linee-guida in ambito clinico per il Melanoma cutaneo

Author

Rossi Cr, Silvestrini R, Ascierto P, Bianchi Scarra' G, Borgognoni L, Chiarion Sileni V, Corti L, De Giorgi V, De Gobbi R, Di Filippo F, Maio M, Massi D, Mocellin S, Mottolese M, Mozzillo N, Palmieri G, Queirolo P, Rivoltini L, Schiavon M, Stanganelli I, Talamini R, Testori A, Caracò C, Pasquali S, Visca P, Bajetta E, Bernengo Mg, Bono R, Botti G, Cascinelli N, Catricala’ C, Chiarugi A, Clemente C, Crocetti E, Fargnoli Mc, Ferraresi V, Gandini S, Ghiorzo P, Guida M, Natali Pg, Parmiani G, Pizzichetta Ma, Ridolfi R, Santinami M, Zanovello P, Rossi, Cr, Silvestrini, R, Ascierto, P, Bianchi Scarra', G, Borgognoni, L, Chiarion Sileni, V, Corti, L, De Giorgi, V, De Gobbi, R, Di Filippo, F, Maio, M, Massi, D, Mocellin, S, Mottolese, M, Mozzillo, N, Palmieri, G, Queirolo, P, Rivoltini, L, Schiavon, M, Stanganelli, I, Talamini, R, Testori, A, Caracò, C, Pasquali, S, Visca, P, Bajetta, E, Bernengo, Mg, Bono, R, Botti, G, Cascinelli, N, Catricala’, C, Chiarugi, A, Clemente, C, Crocetti, E, Fargnoli, Mc, Ferraresi, V, Gandini, S, Ghiorzo, P, Guida, M, Natali, Pg, Parmiani, G, Pizzichetta, Ma, Ridolfi, R, Santinami, M, and Zanovello, P

Subjects
diagnosi, tadiazione, follow-up, Melanoma, stadiazione, terapia
Abstract

"-"

Published
2012

27. Future perspectives in melanoma research: meeting report from the 'Melanoma Bridge': Napoli, December 3rd-6th 2014

Author

Ascierto, PA, Atkins, M, Bifulco, C, Botti, G, Cochran, A, Davies, M, Demaria, S, Dummer, R, Ferrone, S, Formenti, S, Gajewski, TF, Garbe, C, Khleif, S, Kiessling, R, Lo, R, Lorigan, P, Mc Arthur, G, Masucci, G, Melero, I, Mihm, M, Palmieri, G, Parmiani, G, Puzanov, I, Romero, P, Schilling, B, Seliger, B, Stroncek, D, Taube, J, Tomei, S, Zarour, HM, Testori, A, Wang, E, Galon, J, Ciliberto, G, Mozzillo, N, Marincola, FM, Thurin, M, Ascierto, PA, Atkins, M, Bifulco, C, Botti, G, Cochran, A, Davies, M, Demaria, S, Dummer, R, Ferrone, S, Formenti, S, Gajewski, TF, Garbe, C, Khleif, S, Kiessling, R, Lo, R, Lorigan, P, Mc Arthur, G, Masucci, G, Melero, I, Mihm, M, Palmieri, G, Parmiani, G, Puzanov, I, Romero, P, Schilling, B, Seliger, B, Stroncek, D, Taube, J, Tomei, S, Zarour, HM, Testori, A, Wang, E, Galon, J, Ciliberto, G, Mozzillo, N, Marincola, FM, and Thurin, M

Abstract

The fourth "Melanoma Bridge Meeting" took place in Naples, December 3-6th, 2014. The four topics discussed at this meeting were: Molecular and Immunological Advances, Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers. Until recently systemic therapy for metastatic melanoma patients was ineffective, but recent advances in tumor biology and immunology have led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS). New therapies, such as mitogen-activated protein kinase (MAPK) pathway inhibitors as well as other signaling pathway inhibitors, are being tested in patients with metastatic melanoma either as monotherapy or in combination, and all have yielded promising results. These include inhibitors of receptor tyrosine kinases (BRAF, MEK, and VEGFR), the phosphatidylinositol 3 kinase (PI3K) pathway [PI3K, AKT, mammalian target of rapamycin (mTOR)], activators of apoptotic pathway, and the cell cycle inhibitors (CDK4/6). Various locoregional interventions including radiotherapy and surgery are still valid approaches in treatment of advanced melanoma that can be integrated with novel therapies. Intrinsic, adaptive and acquired resistance occur with targeted therapy such as BRAF inhibitors, where most responses are short-lived. Given that the reactivation of the MAPK pathway through several distinct mechanisms is responsible for the majority of acquired resistance, it is logical to combine BRAF inhibitors with inhibitors of targets downstream in the MAPK pathway. For example, combination of BRAF/MEK inhibitors (e.g., dabrafenib/trametinib) have been demonstrated to improve survival compared to monotherapy. Application of novel technologies such sequencing have proven useful as a tool for identification of MAPK pathway-alternative resistance mechanism and designing other combinatorial therapies such as those between BRAF and AKT inhibitors. Improved surviv

Published
2015

28. Late abstracts 186–187

Author

Jaehne, J., Meyer, H. -J., Wittekind, Ch., Maschek, H., Pichlmayr, R., Jacobi, G., Weiermann, G., Vitzthum, H. Gräfin, Schwabe, D., Manegold, Ch., Krempien, B., Kaufmann, M., Bailly, M., Doré, J. -F., Fodstad, Ø., Kjønniksen, I., Brøgger, A., Flørenes, V. A., Pihl, A., Aamdal, S., Nesland, J. M., Geldof, A. A., Rao, B. R., De Giovanni, C., Lollini, P. -L., Del Re, B., Scotlandi, K., Nicoletti, G., Nanni, P., Van Muijen, G. N. P., Van Der Wiel-Miezenbeek, J. M., Cornelissen, L. M. H. A., Jansen, C. F. J., Ruiter, D. J., Kieler, J., Oda, Y., Tokuriki, Y., Tenang, E. M., Lamb, J. F., Galante, E., Zanoni, F., Galluzzi, D., Cerrotta, A., Martelli, G., Guzzon, A., Reduzzi, D., Barberá-Guillem, E., Barceló, J. R., Urcelay, B., Alonso-Varona, A. I., Vidal-Vanaclocha, F., Bassukas, I. D., Maurer-Schultze, B., Storeng, R., Manzotti, C., Pratesi, G., Schachert, G., Fidler, I. J., Grimstad, I. A., Rutt, G. Th., Riesinger, P., Frank, J., Neumann, G., Wissler, J. H., Bastert, G., Liebrich, W., Lehner, B., Gonzer, S., Schlag, P., Vehmeyer, K., Hajto, T., Gabius, H. -J., Funke, I., Schlimok, G., Bock, B., Dreps, A., Schweiberer, B., Riethmüller, G., Nicolai, U., Vykoupil, K. -F., Wolf, M., Havemann, K., Georgii, A., Bertrand, S., N'Guyen, M. -J., Siracky, J., Kysela, B., Siracka, E., Pflüger, E., Schirrmacher, V., Boyano, M. D., Hanania, N., Poupon, M. F., Sherbet, G. V., Lakshmi, M. S., Van Roy, F., Vleminckx, K., Fiers, W., Dragonetti, C., De Bruyne, G., Messiaen, L., Mareel, M., Kuhn, S., Choritz, H., Schmid, U., Bihl, H., Griesbach, A., Matzku, S., Eccles, S. A., Purvies, H. P., Miller, F. R., McEachern, D., Ponton, A., Waghorne, C., Coulombe, B., Kerbel, R. S., Breitman, M., Skup, D., Gingras, M. C., Jarolim, L., Wright, J. A., Greenberg, A. H., N'Guyen, M. J., Allavena, G., Melchiori, A., Aresu, O., Percario, M., Parodi, S., Schmidt, J., Kars, P., Chader, G., Albini, A., Zöller, M., Lissitzky, J. C., Bouzon, M., Martin, P. M., Grossi, I. M., Taylor, J. D., Honn, K. V., Koch, B., Baum, W., Giedl, J., Gabius, H. J., Kalden, J. R., Hakim, A. A., LadÁnyi, A., Timár, J., Moczar, E., Lapis, K., Müller, K., Wolf, M. F., Benz, B., Schumacher, K., Kemmner, W., Morgenthaler, J., Brossmer, R., Hagmar, B., Burns, G., Erkell§, L. J., Ryd, W., Paku, S., Rot, A., Hilario, E., Unda, F., Simón, J., Aliño, S. F., Sargent, N. S. E., Burger, M. M., Altevogt, P., Kowitz, A., Chopra, H., Bandlow, G., Nagel, G. A., Lotan, R., Carralero, D., Lotan, D., Raz, A., Skubitz, A. P. N., Koliakos, G. G., Furcht, L. T., Charonis, A. S., Hamann, A., Jablonski-Westrich, D., Jonas, P., Harder, R., Butcher, E. C., Thiele, H. G., Breillout, F., Antoine, E., Lascaux, V., Boxberger, H. -J., Paweletz, N., Bracke, M., Vyncke, B., Opdenakker, G., Castronovo, V., Foidart, J. -M., Camacho, M., Fras, A. Fabra, Llorens, A., Rutllant, M. L., Erkell, L. J., Brunner, G., Heredia, A., Imhoff, J. M., Burtin, P., Nakajima, M., Lunec, J., Parker, C., Fennelly, J. A., Smith, K., Roossien, F. F., La Rivière, G., Roos, E., Erdel, M., Trefz, G., Spiess, E., Ebert, W., Verhaegen, S., Remels, L., Verschueren, H., Dekegel, D., De Baetselier, P., Van Hecke, D., Hannecart-Pokorni, E., Falkvoll, K. H., Alonso, A., Baroja, A., Sebbag, U., Barbera-Guillem, E., Behrens, J., Mareel, M. M., Birchmeier, W., Waterhouse, P., Khokha, R., Chambers, A., Yagel, S., Lala, P. K., Denhardt, D. T., Hennes, R., Frantzen, F., Keller, R., Schwartz-Albiez, R., Fondaneche, M. C., Mignatti, P., Tsuboi, R., Robbins, E., Rifkin, D. B., Overall, C. M., Sacchi, A., Falcioni, R., Piaggio, G., Rizzo, M. G., Perrotti, N., Kennel, S. J., Girschick, H., Müller-Hermelink, H. K., Vollmers, H. P., Wenzel, A., Liu, S., Günthert, U., Wesch, V., Giles, M., Ponta, H., Herrlich, P., Stade, B., Hupke, U., Holzmann, B., Johnson, J. P., Sauer, A., Roller, E., Klumpp, B., Güttler, N., Lison, A., Walk, A., Redini, F., Moczar, M., Leoni, F., Da Dalt, M. G., Ménard, S., Canevari, S., Miotti, S., Tagliabue, E., Colnaghi, M. I., Ostmeier, H., Suter, L., Possati, L., Rosciani, C., Recanatini, E., Beatrici, V., Diambrini, M., Polito, M., Rothbächer, U., Eisenbach, L., Plaksin, D., Gelber, C., Kushtai, G., Gubbay, J., Feldman, M., Benke, R., Benedetto, A., Elia, G., Sala, A., Belardelli, F., Lehmann, J. M., Ladanyi, A., Hanisch, F. -G., Sölter, J., Jansen, V., Böhmer, G., Peter-Katalinic, J., Uhlenbruck, G., O'Connor, R., Müller, J., Kirchner, T., Bover, B., Tucker, G., Valles, A. M., Gavrilovic, J., Thiery, J. P., Kaufmann, A. M., Volm, M., Edel, G., Zühlsdorf, M., Voss, H., Wörmann, B., Hiddemann, W., De Neve, W., Van Den Berge, D., Van Loon, R., Storme, G., Zacharski, L. R., Wojtukiewicz, M. Z., Memoli, V., Kisiel, W., Kudryk, B. J., Stump, D., Piñol, G., Gonzalez-Garrigues, M., Fabra, A., Marti, F., Rueda, F., Lichtner, R. B., Khazaie, K., Timar, J., Greenzhevskaya, S. N., Shmalko, Yu. P., Hill, S. E., Rees, R. C., MacNeil, S., Millon, R., Muller, D., Eber, M., Abecassis, J., Betzler, M., Bahtsky, K. P., Umansky, V. Yu., Krivorotov, A. A., Balitskaya, E. K., Pridatko, O. E., Smelkova, M. I., Smirnov, I. M., Korczak, B., Fisher, C., Thody, A. J., Young, S. D., Hill, R. P., Frixen, U., Gopas, J., Segal, S., Hammerling, G., Bar-Eli, M., Rager-Zisman, B., Har-Vardi, I., Alon, Y., Hämmerling, G. J., Perez, M., Algarra, I., Collado, Ma. D., Peran, E., Caballero, A., Garrido, F., Turner, G. A., Blackmore, M., Stern, P. L., Thompson, S., Levin, I., Kuperman, O., Eyal, A., Kaneti, J., Notter, M., Knuth, A., Martin, M., Chauffert, B., Caignard, A., Hammann, A., Martin, F., Dearden, M. T., Pelletier, H., Dransfield, I., Jacob, G., Rogers, K., Pérez-Yarza, G., Cañavate, M. L., Lucas, R., Bouwens, L., Mantovani, G., Serri, F. G., Macciò, A., Zucca, M. V., Del Giacco, G. S., Pérez, M., Kärre, K., Apt, D., Traversari, C., Sensi, M., Carbone, G., Parmiani, G., Hainaut, P., Weynants, P., Degiovanni, G., Boon, T., Marquardt, P., Stulle, K., Wölfel, T., Herin, M., Van den Eynde, B., Klehmann, E., Büschenfelde, K. -H. Meyer zum, Samija, M., Gerenčer, M., Eljuga, D., Bašić, I., Heacock, C. S., Blake, A. M., D'Aleo, C. J., Alvarez, V. L., Gresser, I., Maury, C., Moss, J., Woodrow, D., von Ardenne, M., Krüger, W., Möller, P., Schachert, H. K., Itaya, T., Frost, P., Rodolfo, M., Salvi, C., Bassi, C., Huland, E., Huland, H., Sersa, G., Willingham, V., Hunter, N., Milas, L., Schild, H., von Hoegen, P., Mentges, B., Bätz, W., Suzuki, N., Mizukoshi, T., Sava, G., Ceschia, V., Zabucchi, G., Farkas-Himsley, H., Schaal, O., Klenner, T., Keppler, B., Alvarez-Diaz, A., Bizzari, J. P., Barbera-Guillem, F., Osterloh, B., Bartkowski, R., LÖhrke, H., Schwahn, E., Schafmayer, A., Goerttler, K., Cillo, C., Ling, V., Giavazzi, R., Vecchi, A., Luini, W., Garofalo, A., Iwakawa, M., Arundel, C., Tofilon, P., Giraldi, T., Perissin, L., Zorzet, S., Piccini, P., Pacor, S., Rapozzi, V., Fink, U., Zeuner, H., Dancygier, H., Classen, M., Lersch, C., Reuter, M., Hammer, C., Brendel, W., Mathé, G., Bourut, C., Chenu, E., Kidani, Y., Mauvernay, Y., Schally, A. V., Reizenstein, P., Gastiaburu, J., Comaru-Schally, A. M., Cupissol, D., Jasmin, C., Missot, J. L., Wingen, F., Schmähl, D., Pauwels-Vergely, C., Poupon, M. -F., Gasic, T. B., Ewaskiewicz, J. I., Gasic, G. J., Pápay, J., Mauvernay, R., Schally, A., Keiling, R., Hagipantelli, R., Busuttil, M., VoVan, M. L., Misset, J. L., Lévi, F., Musset, M., Ribaud, P., Hilgard, P., Reissmann, T., Stekar, J., Voegeli, R., Den Otter, W., Maas, H. A., Dullens, H. F. J., Merriman, R. L., Tanzer, L. R., Shackelford, K. A., Bemis, K. G., Campbell, J. B., and Matsumoto, K.

Published
1988
Full Text
View/download PDF

30. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012

Author

Maio, M., Nicolay, H. J. M., Ascierto, P. A., Belardelli, F., Camerini, R., Colombo, M. P., Queirolo, P., Ridolfi, R., Russo, V., Parisi, G., Cutaia, O., Fonsatti, E., Parmiani, G., Mennonna, D., Carluccio, S., Bellone, M., Maccalli, C., Brendolan, A., Mondino, A., Corti, A., Bondanza, A., Locatelli, F., Seliger, B., Filaci, G., Rosato, A., Pittoni, P., Tazzari, M., Rivoltini, L., Anichini, A., Vallacchi, V., Zappasodi, R., Quaglino, E., Moresco, R. M., Camisaschi, C., Calabro, L., Ferrucci, P. F., Fratta, E., Ugel, S., van Baren, N., Guidoboni, M., Covre, A., Carbone, E., Aurisicchio, L., Palmieri, G., Di Giacomo, A. M., Volonte, A., Jachetti, E., and Sangiolo, D.

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Immunology, Cancer, medicine.disease, NIBIT, Oncology, Family medicine, Immunotherapy, Networks, Cancer, Immunology, Immunotherapy, Networks, NIBIT, Immunology and Allergy, Medicine, business
Published
2013

32. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

Author

Maio, M, Nicolay, Hj, Ascierto, Pa, Belardelli, F, Camerini, R, Colombo, Mp, Queirolo, P, Ridolfi, R, Russo, V, Fonsatti, E, Parmiani, G, Allavena P, N. I. B. I. T., Anichini, A, Bellone, M, Bronte, V, Calabrò, L, Camisaschi, C, Castelli, C, Danova, M, Di Giacomo AM, Di Nicola, M, Ferlazzo, G, Giovannoni, L, Hwu, P, Lehmann, F, Maccalli, C, Melero, I, Monsurro', Vladia, Montagna, D, Moschella, F, Ponzoni, M, Protti, Mp, Puccetti, P, Sangiolo, D, and Schuler, G.

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Immunology, Neoplasms therapy, Immunotherapy, Immunomodulatory therapy, adoptive cell therapy, Oncology, medicine, Immunology and Allergy, Medical physics, business
Published
2010

33. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

Author

Maio, M. (Michele), Nicolay, H.J.M. (Hugues J.M.), Ascierto, P.A. (Paolo Antonio), Belardelli, F. (Filipppo), Camerini, R. (Roberto), Colombo, M.P. (Mario P.), Queirolo, P. (Paola), Ridolfi, R. (Ruggero), Russo, V. (Vicenzo), Fonsati, E. (Ester), Parmiani, G. (Giorgio), Allavena, P. (P), Anichini, A. (A), Bellone, M. (M), Bronstein, J. (Judith), Calabro, L. (L), Camisaschi, C. (C), Castelli, C. (Chiara), Danova, M. (M), Di-Giacomo, A.M. (A.M.), Di-Nicola, M. (Massimo), Ferlazzo, G. (G.), Giovannoni, L. (L.), Hwu, P. (Patrick), Lehmann, F. (F.), Maccalli, C. (Cristina), Melero, I. (Ignacio), Monsurro, V. (V), Montagna, D. (D.), Moschella, F. (F.), Ponzoni, M. (M), Protti, M.P. (M.P.), Puccetti, P. (P), Sangiolo, D. (D.), and Shuler, G. (G)

Subjects
Neoplasms/therapy
Published
2010

34. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT)

Author

Maio, M, Nicolay, Hj, Ascierto, Pa, Belardelli, F, Camerini, R, Colombo, Mp, Queirolo, P, Ridolfi, R, Russo, V, Fonsatti, E, Parmiani, G, Calabro', L, and Nibit, Collaborators

Subjects
Angiogenesis Inhibitors, Cancer Vaccines, Dendritic Cells, Humans, Immune Tolerance, Immunotherapy, Adoptive, Neoplasms, Tumor Escape, Vaccination, Adoptive, Immunotherapy, NO
Published
2010

35. Awareness and understanding of cancer immunotherapy in Europe

Author

Mellstedt, H., Gaudernack, G., Gerritsen, W.R., Huber, C., Melero, I., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Mellstedt, H., Gaudernack, G., Gerritsen, W.R., Huber, C., Melero, I., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., and Zielinski, C.

Abstract

Item does not contain fulltext, The use of immunotherapy in the management of cancer is growing, and a range of new immunotherapeutic strategies is becoming available. It is important that people involved in the care of cancer understand how cancer immunotherapies differ from conventional chemotherapy and apply this knowledge to their clinical practice. Therefore, from August-September 2011 we undertook a survey of awareness, attitudes, and perceptions of cancer immunotherapy among 426 healthcare professionals (HCPs) in Europe with the aim of identifying and prioritizing educational needs. Nearly all (98%) HCPs were aware of cancer immunotherapy. While 68% of HCPs indicated a high level of interest in cancer immunotherapies, only 24% of the HCPs had direct experience with them. Overall perceptions of cancer immunotherapy among HCPs were largely positive (60%) and rarely negative (3%). The key advantages of cancer immunotherapy were perceived to be good safety and tolerability (75%), a targeted mechanism of action (61%) and good efficacy (48%). The leading barriers to use of immunotherapies were costs of treatment (58%), past clinical trial failures (45%), and access/formulary restrictions (44%). The results indicate that, among the respondents, awareness of cancer immunotherapy was high but that knowledge levels varied and direct experience with their use was limited. There appears to be a need for educational activities on cancer immunotherapy, as well as generation and communication of clinical data on long-term efficacy and safety.

Published
2014

36. Therapeutic vaccines for cancer: an overview of clinical trials

Author

Melero, I., Gaudernack, G., Gerritsen, W.R., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., Mellstedt, H., Melero, I., Gaudernack, G., Gerritsen, W.R., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., and Mellstedt, H.

Abstract

Item does not contain fulltext, The therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy.

Published
2014

37. Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls

Author

Casula, M, Alaibac, M, Pizzichetta, Ma, Bono, R, Ascierto, Pa, Stanganelli, I, Canzanella, S, Palomba, G, Zattra, E, Palmieri, G, Bianchi, Giovanna, Sileni, Vc, Di Filippo, F, Maio, M, Parmiani, G, Queirolo, P, Ridolfi, R, Rossi, C, Testori, A., Casula, M, Alaibac, M, Pizzichetta, Ma, Bono, R, Ascierto, Pa, Stanganelli, I, Canzanella, S, Palomba, G, and Zattra, E

Subjects
Adult, Male, Skin Neoplasms, Genotype, melanoma susceptibility, Single-nucleotide polymorphism, Dermatology, Biology, Polymorphism, Single Nucleotide, Pathogenesis, Young Adult, Risk Factors, Polymorphism (computer science), Prevalence, medicine, melanoma, lcsh:Dermatology, Humans, Genetic Predisposition to Disease, Allele, neoplasms, integumentary system, Epidermal Growth Factor, Melanoma, Middle Aged, lcsh:RL1-803, medicine.disease, Genotype frequency, Italy, Immunology, Cutaneous melanoma, Female, Research Article
Abstract

Background A single nucleotide polymorphism (61A>G) in the epidermal growth factor (EGF) gene has been implicated in both melanoma pathogenesis and increased melanoma risk. To further evaluate this association, we conducted a case-control study in a clinic-based Italian population. Methods Individuals with less than 10 (N = 127) or more than 100 (N = 128) benign nevi, and patients with cutaneous melanoma (N = 418) were investigated for the EGF +61A>G polymorphism, using an automated sequencing approach. Results Overall, no difference in EGF genotype frequencies was observed among subjects with different number of nevi as well as when non-melanoma healthy controls were compared with the melanoma patients. However, a heterogeneous distribution of the frequencies of the G/G genotype was detected among cases and controls originating from North Italy (21.1 and 18.3%, respectively) vs. those from South Italy (12.6 and 17.1%, respectively). Conclusion Our findings further suggest that EGF +61A>G polymorphism may have a limited impact on predisposition and/or pathogenesis of melanoma and its prevalence may vary in different populations.

Published
2009
Full Text
View/download PDF

38. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)- defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage

Author

Lupetti R., Pisarra P., Verrecchia A., Farina C., Nicolini G., Anichini A., Sensi M., Parmiani G., C. Traversari, BORDIGNON , CLAUDIO, Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., Bordignon, Claudio, Sensi, M., Parmiani, G., and C., Traversari

Published
1998

39. Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients

Author

Spinazzé, S, Viviani, S, Bidoli, P, Rovelli, F, Palmer, P, Franks, C, Arienti, F, Rivoltini, L, Parmiani, G, Spinazzé S, Viviani S, Bidoli P, Rovelli F, Palmer P, Franks CR, Arienti F, Rivoltini L, Parmiani G., Spinazzé, S, Viviani, S, Bidoli, P, Rovelli, F, Palmer, P, Franks, C, Arienti, F, Rivoltini, L, Parmiani, G, Spinazzé S, Viviani S, Bidoli P, Rovelli F, Palmer P, Franks CR, Arienti F, Rivoltini L, and Parmiani G.

Abstract

Interleukin-2 has been shown to stimulate cortisol secretion in man. Owing to its immunosuppressive properties, an increase in cortisol levels during interleukin-2 cancer immunotherapy could potentially counteract induced activation of the antitumor immune response. Few data are available about cortisol secretion secondary to prolonged interleukin-2 administration. To investigate the problem, we evaluated cortisol circadian rhythms in 7 consecutive metastatic small cell lung cancer patients who received interleukin-2 subcutaneously for 4 weeks (daily dose: 6 x 10(6) x IU/m2). Venous blood samples were drawn at 8.00 a.m., 4.00 p.m. and 12.00 p.m., before interleukin-2, and after each week until the end of the cycle. Beta-endorphin levels were also measured on the same samples. Four patients were evaluated during a second interleukin-2 cycle. Mean cortisol levels increased during interleukin-2 therapy, but were significantly higher than those seen in basal conditions after the first week of treatment. Moreover, cortisol peaks observed during the second cycle of therapy were not significantly different from those seen during the first cycle. Mean beta-endorphin levels increased in response to interleukin-2 administration, but the increase did not reach statistical significance. The early cortisol rise progressively decreased as treatment continued. This suggests that the interleukin-2-induced cortisol rise has no relevant clinical importance in antagonizing the activation of an effective antitumor immune response during cancer immunotherapy with interleukin-2

Published
1991

Catalog

Books, media, physical & digital resources
See catalog results